Coronavírus Página 7

NEJM - Durability of Responses after SARS-CoV-2 mRNA-1273 Vaccination

The New England Journal of MedicineWe recently reported the results of a phase 1 trial of a messenger RNA vaccine, mRNA-1273, to prevent infection with SARS-CoV-2; those interim results covered a period of 57 days after the first vaccination.

WHO - Mask use in the context of COVID-19

World Health OrganizationThis document provides updated guidance on mask use in health care and community settings, and during home care for COVID-19 cases. It is intended for policy makers, public health and infection prevention and control...

ECDC - Updated projections of COVID-19 in the EU/EEA and the UK

European Centre for Disease Prevention and ControlFollowing widespread transmission of SARS-CoV-2 in the European Union (EU)/European Economic Area (EEA) countries and the United Kingdom (UK) over several weeks, the COVID-19 epidemic reached a...

DGS - Plano de Vacinação contra a COVID-19

Direção-Geral da Saúde

A COVID-19, causada por um novo coronavírus identificado pela primeira vez em Wuhan, China (SARS-CoV-2), foi reconhecida como pandemia pela Organização Mundial de Saúde (OMS) no dia 11 de março de 2020.

ECDC - Contact tracing: public health management of persons, including healthcare workers, who have had contact with COVID-19 cases in the European Union – third update

European Centre for Disease Prevention and ControlThis document aims to help public health authorities in EU/EEA countries and the UK in their tracing and management of persons, including healthcare workers, who have had contact with COVID-19...

WHO - Therapeutics and COVID-19: living guideline

World Health OrganizationCurrent practice to treat COVID-19 is variable, reflecting large-scale uncertainty. Numerous randomized controlled trials (RCTs) of many different drugs are underway to inform practice. This version of the World Health...

WHO - Priority medical devices list for the COVID-19 response and associated technical specifications

World Health OrganizationThis document describes the medical devices required for the clinical management of COVID-19, selected and prioritized according to the latest available evidence and interim guidelines.

ECDC - Options for the use of rapid antigen tests for COVID-19 in the EU/EEA and the UK

European Centre for Disease Prevention and ControlRapid antigen tests can contribute to overall COVID-19 testing capacity, offering advantages in terms of shorter turnaround times and reduced costs, especially in situations in which RT-PCR...

ECDC - Rapid Risk Assessment: Increase in fatal cases of COVID-19 among long-term care facility residents in the EU/EEA and the UK

European Centre for Disease Prevention and ControlObserved all-cause mortality among older people underlines the severe impact of COVID-19 in this population group. Residents in long-term care facilities (LTCFs) are one of the most vulnerable...

WHO - Technical specifications of personal protective equipment for COVID-19

World Health OrganizationThis document provides interim guidance on the quality, performance characteristics and related standards of personal protective equipment (PPE) to be used in the context of COVID-19. This includes WHO Priority Medical...

WHO - Guidance on developing a national deployment and vaccination Planning for COVID-19 vaccines

World Health Organization

The Guidance on National Deployment and Vaccination Planning is intended to help countries develop their plan for COVID-19 vaccine introduction.

ECDC - Heating, ventilation and air-conditioning systems in the context of COVID-19: first update

European Centre for Disease Prevention and Control
This document provides guidance on heating, ventilation and air-conditioning (HVAC) systems in closed spaces in the context of the COVID-19 pandemic.

Comissão Europeia - A NEW DRIVE FOR PRIMARY CARE IN EUROPE: RETHINKING THE ASSESSMENT TOOLS AND METHODOLOGIES

Comissão Europeia

Report of the Expert Group on Health Systems Performance Assessment.

BMJ - Risk of hospital admission with coronavirus disease 2019 in healthcare workers and their households: nationwide linkage cohort study

British Medical Journal
To assess the risk of hospital admission for coronavirus disease 2019 (covid-19) among patient facing and non-patient facing healthcare workers and their household members.

NEJM - Remdesivir for 5 or 10 Days in Patients with Severe Covid-19

The New England Journal of Medicine

Remdesivir is an RNA polymerase inhibitor with potent antiviral activity in vitro and efficacy in animal models of coronavirus disease 2019 (Covid-19).